Harwin Peter Evan

SEC source: 0001104659-24-100330 · tm2424157-1_4seq1.xml · derivative · entry 8

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II LP

Disclosed balance after: 0

Underlying: Common Stock · 709,794 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4 · price: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4 · derivative.exercise_date: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4 · derivative.expiration_date: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II"). The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-100330 · tm2424157-1_4seq1.xml · derivative · entry 7

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II LP

Disclosed balance after: 0

Underlying: Common Stock · 252,890 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F3 · price: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F3 · derivative.exercise_date: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F3 · derivative.expiration_date: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II"). The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-100330 · tm2424157-1_4seq1.xml · derivative · entry 6

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II LP

Disclosed balance after: 0

Underlying: Common Stock · 41,130 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · price: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · derivative.exercise_date: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · derivative.expiration_date: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II"). The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-100330 · tm2424157-1_4seq1.xml · nonDerivative · entry 5

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II LP

Disclosed balance after: 1,604,891

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II"). The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-100330 · tm2424157-1_4seq1.xml · nonDerivative · entry 4

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II LP

Disclosed balance after: 1,304,891

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F5 · price: On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II"). The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-100330 · tm2424157-1_4seq1.xml · nonDerivative · entry 3

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II LP

Disclosed balance after: 1,003,814

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4 · price: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II"). The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-100330 · tm2424157-1_4seq1.xml · nonDerivative · entry 2

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II LP

Disclosed balance after: 294,020

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F3 · price: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II"). The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-100330 · tm2424157-1_4seq1.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II LP

Disclosed balance after: 41,140

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · price: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II"). The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-100766 · tm2424157-13_4aseq1.xml · derivative · entry 9

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II LP

Disclosed balance after: 0

Underlying: Common Stock · 301,077 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F6 · price: On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F6 · derivative.exercise_date: On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F6 · derivative.expiration_date: On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F3 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II"). The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-100766 · tm2424157-13_4aseq1.xml · derivative · entry 8

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II LP

Disclosed balance after: 0

Underlying: Common Stock · 709,794 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F5 · price: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F5 · derivative.exercise_date: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F5 · derivative.expiration_date: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F3 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II"). The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-100766 · tm2424157-13_4aseq1.xml · derivative · entry 7

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II LP

Disclosed balance after: 0

Underlying: Common Stock · 252,890 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II"). The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F4 · price: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4 · derivative.exercise_date: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4 · derivative.expiration_date: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F3 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II"). The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-100766 · tm2424157-13_4aseq1.xml · derivative · entry 6

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II LP

Disclosed balance after: 0

Underlying: Common Stock · 41,130 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · price: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · derivative.exercise_date: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · derivative.expiration_date: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F3 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II"). The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-100766 · tm2424157-13_4aseq1.xml · nonDerivative · entry 5

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II LP

Disclosed balance after: 1,892,806

F2 · balance_after: The original Form 4, filed on September 16, 2024 is being amended by this Form 4 solely to correct the previously reported "Amount of Securities Beneficially Owned Following Reported Transactions." This amended Form 4 does not report any new transactions or otherwise modify the transaction details that were previously reported.

F3 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II"). The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-100766 · tm2424157-13_4aseq1.xml · nonDerivative · entry 4

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II LP

Disclosed balance after: 1,592,806

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · kind: On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F6 · price: On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2 · balance_after: The original Form 4, filed on September 16, 2024 is being amended by this Form 4 solely to correct the previously reported "Amount of Securities Beneficially Owned Following Reported Transactions." This amended Form 4 does not report any new transactions or otherwise modify the transaction details that were previously reported.

F3 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II"). The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-100766 · tm2424157-13_4aseq1.xml · nonDerivative · entry 3

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II LP

Disclosed balance after: 1,291,729

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F5 · price: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2 · balance_after: The original Form 4, filed on September 16, 2024 is being amended by this Form 4 solely to correct the previously reported "Amount of Securities Beneficially Owned Following Reported Transactions." This amended Form 4 does not report any new transactions or otherwise modify the transaction details that were previously reported.

F3 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II"). The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-100766 · tm2424157-13_4aseq1.xml · nonDerivative · entry 2

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II LP

Disclosed balance after: 581,935

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4 · price: On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2 · balance_after: The original Form 4, filed on September 16, 2024 is being amended by this Form 4 solely to correct the previously reported "Amount of Securities Beneficially Owned Following Reported Transactions." This amended Form 4 does not report any new transactions or otherwise modify the transaction details that were previously reported.

F3 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II"). The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-100766 · tm2424157-13_4aseq1.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II LP

Disclosed balance after: 329,045

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · price: On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2 · balance_after: The original Form 4, filed on September 16, 2024 is being amended by this Form 4 solely to correct the previously reported "Amount of Securities Beneficially Owned Following Reported Transactions." This amended Form 4 does not report any new transactions or otherwise modify the transaction details that were previously reported.

F3 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II"). The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-100330 · tm2424157-1_4seq1.xml · derivative · entry 10

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Tomas Kiselak

Disclosed balance after: 37,000

Underlying: Common Stock · 37,000 shares

Expires 2034-09-11

F6 · derivative.exercise_date: The option vests in equal annual installments over three years beginning on September 12, 2025, the first anniversary of the vesting commencement date, subject to continued service.

F7 · ownership.nature: Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

SEC source: 0001104659-24-100766 · tm2424157-13_4aseq1.xml · derivative · entry 10

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Tomas Kiselak

Disclosed balance after: 37,000

Underlying: Common Stock · 37,000 shares

Expires 2034-09-11

F7 · derivative.exercise_date: The option vests in equal annual installments over three years beginning on September 12, 2025, the first anniversary of the vesting commencement date, subject to continued service.

F8 · ownership.nature: Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

SEC source: 0001213900-24-078633 · ownership.xml · derivative · entry 3

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II L.P.

Disclosed balance after: 160

Underlying: Common Stock · 160,000 shares

Expires not disclosed

F3 · derivative.exercise_price: Following stockholder approval of the conversion of the Series A non-voting convertible preferred stock (the "Series A Preferred Stock") into shares of Common Stock, each share of Series A Preferred Stock will automatically convert into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Series A Preferred Stock has no expiration date.

F4 · shares: The shares of Series A Preferred Stock were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended.

F3 · derivative.exercise_date: Following stockholder approval of the conversion of the Series A non-voting convertible preferred stock (the "Series A Preferred Stock") into shares of Common Stock, each share of Series A Preferred Stock will automatically convert into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Series A Preferred Stock has no expiration date.

F3 · derivative.expiration_date: Following stockholder approval of the conversion of the Series A non-voting convertible preferred stock (the "Series A Preferred Stock") into shares of Common Stock, each share of Series A Preferred Stock will automatically convert into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Series A Preferred Stock has no expiration date.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001213900-24-078633 · ownership.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II L.P.

Disclosed balance after: 638,614

F1 · kind: The shares of Common Stock were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000950170-24-079044 · ownership.xml · derivative · entry 1

Harwin Peter Evan · CIK 0001663607 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 21,000

Underlying: Common Stock · 21,000 shares

Expires 2034-06-26

F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) June 26, 2025 or (ii) the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board.

F2 · ownership.nature: Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

SEC source: 0001104659-24-069790 · tm2416491-7_4seq1.xml · derivative · entry 2

Fairmount Funds Management LLC · CIK 0001802528 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,370

Underlying: Common Stock · 10,370 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This option represents the right to purchase 10,370 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

F3 · ownership.direct: Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more Fairmount Funds. Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

SEC source: 0001104659-24-069790 · tm2416491-7_4seq1.xml · derivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,370

Underlying: Common Stock · 10,370 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This option represents the right to purchase 10,370 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

F2 · ownership.direct: Under Mr. Harwin's arrangement with Fairmount Funds Management LLC ('Fairmount'), Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

SEC source: 0000950170-24-073231 · ownership.xml · derivative · entry 1

Harwin Peter Evan · CIK 0001663607 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,700

Underlying: Common Stock · 44,700 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2025 Annual Meeting of Stockholders.

F2 · ownership.direct: Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

SEC source: 0000950170-24-061084 · ownership.xml · derivative · entry 2

Fairmount Funds Management LLC · CIK 0001802528 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Tomas Kiselak

Disclosed balance after: 11,323

Underlying: Common Stock · 11,323 shares

Expires 2034-05-14

F3 · derivative.exercise_date: This option represents a right to purchase 11,323 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 14, 2024 until such time as the option is 100% vested, subject to Tomas Kiselak's continuous service with the Issuer at each vesting date.

F4 · ownership.nature: Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Kiselak holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock.

SEC source: 0000950170-24-061084 · ownership.xml · derivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Peter Harwin

Disclosed balance after: 11,323

Underlying: Common Stock · 11,323 shares

Expires 2034-05-14

F1 · derivative.exercise_date: This option represents a right to purchase 11,323 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 14, 2024 until such time as the option is 100% vested, subject to Peter Harwin's continuous service with the Issuer at each vesting date.

F2 · ownership.nature: Under Mr. Harwin's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Harwin holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock.

SEC source: 0000950170-24-048457 · ownership.xml · derivative · entry 4

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II L.P.

Disclosed balance after: 346,045

Underlying: Common Stock · 3,639,680 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of Series A Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.

F1 · kind: Pursuant to an Exchange Agreement between Fairmount Healthcare Fund II L.P. ("Fund II") and the Issuer dated as of April 23, 2024, Fund II exchanged 90,992 shares of Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") for 3,639,680 shares of Common Stock, effective on April 25, 2024.

F3 · derivative.exercise_date: Each share of Series A Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.

F3 · derivative.expiration_date: Each share of Series A Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fund II. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000950170-24-048457 · ownership.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II L.P.

Disclosed balance after: 4,018,101

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Pursuant to an Exchange Agreement between Fairmount Healthcare Fund II L.P. ("Fund II") and the Issuer dated as of April 23, 2024, Fund II exchanged 90,992 shares of Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") for 3,639,680 shares of Common Stock, effective on April 25, 2024.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fund II. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-041998 · tm2410305-2_4seq1.xml · derivative · entry 6

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II LP

Disclosed balance after: 6,743,321

Underlying: Common Stock · 6,521,895 shares

Expires not disclosed

F4 · derivative.exercise_price: The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%.

F1 · kind: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II").

F4 · derivative.exercise_date: The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%.

F4 · derivative.expiration_date: The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%.

F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund II. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund II GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund II GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-041998 · tm2410305-2_4seq1.xml · derivative · entry 5

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund LP

Disclosed balance after: 0

Underlying: Common Stock · 221,426 shares

Expires not disclosed

F4 · derivative.exercise_price: The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%.

F1 · kind: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II").

F4 · derivative.exercise_date: The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%.

F4 · derivative.expiration_date: The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%.

F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund I. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-041998 · tm2410305-2_4seq1.xml · nonDerivative · entry 2

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II LP

Disclosed balance after: 2,048,647

F1 · kind: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II").

F1 · price: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II").

F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund II. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund II GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund II GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-041998 · tm2410305-2_4seq1.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund LP

Disclosed balance after: 0

F1 · kind: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II").

F1 · price: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II").

F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund I. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

SEC source: 0001104659-24-008835 · tm244753-2_4seq1.xml · nonDerivative · entry 3

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Fairmount Healthcare Co-Invest II L.P. · CIK 0001982189 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · By Peter Harwin

Disclosed balance after: 51,166

F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest II LP ("Co-Invest") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023.

SEC source: 0001104659-24-008835 · tm244753-2_4seq1.xml · nonDerivative · entry 2

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Fairmount Healthcare Co-Invest II L.P. · CIK 0001982189 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · By Tomas Kiselak

Disclosed balance after: 51,166

F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest II LP ("Co-Invest") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023.

SEC source: 0001104659-24-008835 · tm244753-2_4seq1.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Fairmount Healthcare Co-Invest II L.P. · CIK 0001982189 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · By Fairmount Healthcare Co-Invest II LP

Disclosed balance after: 0

F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest II LP ("Co-Invest") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund L.P. ("Fund I"), Fairmount Healthcare Fund II L.P. ("Fund II") and Co-Invest. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000950170-24-007136 · ownership.xml · derivative · entry 2

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 832,333

Underlying: Common Stock · 832,333 shares

Expires not disclosed

F3 · shares: Consists of Pre-Funded Warrants to purchase up to 832,333 shares of common stock purchased by Fund II from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Exchange Act.

F4 · derivative.exercise_date: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.

F4 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.

F5 · ownership.nature: Consists of Pre-Funded Warrants to purchase up to 832,333 shares of common stock held of record by Fund II. Fairmount is the investment manager for Fund II. The general partner of Fairmount is Fairmount GP, of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000950170-24-007136 · ownership.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 2,762,837

F1 · shares: Consists of 834,334 shares of common stock purchased by Fairmount Healthcare Fund II LP ("Fund II") from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · ownership.nature: Consists of (i) 58,857 shares of common stock held of record by Fairmount Healthcare Fund LP ("Fund I"), (ii) 2,641,834 shares of common stock held of record by Fund II and (iii) 62,146 shares of common stock held of record by Fairmount SPV III, LLC. Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fund I and Fund II and is the Class A Member for Fairmount SPV III, LLC. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000950170-23-073904 · ownership.xml · nonDerivative · entry 3

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Fairmount Healthcare Co-Invest L.P. · CIK 0001982220 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · By Peter Harwin

Disclosed balance after: 406,038

F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest L.P. ("Co-Invest") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023.

SEC source: 0000950170-23-073904 · ownership.xml · nonDerivative · entry 2

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Fairmount Healthcare Co-Invest L.P. · CIK 0001982220 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · By Tomas Kiselak

Disclosed balance after: 406,038

F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest L.P. ("Co-Invest") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023.

SEC source: 0000950170-23-073904 · ownership.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Fairmount Healthcare Co-Invest L.P. · CIK 0001982220 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · By Fairmount Healthcare Co-Invest L.P.

Disclosed balance after: 0

F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest L.P. ("Co-Invest") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund L.P. ("Fund I"), Fairmount Healthcare Fund II L.P. ("Fund II") and Co-Invest. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000950170-23-069455 · ownership.xml · derivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Fairmount Healthcare Co-Invest L.P. · CIK 0001982220 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II L.P.

Disclosed balance after: 16,667

Underlying: Common Stock · 666,680 shares

Expires not disclosed

F1 · derivative.exercise_price: Following stockholder approval of the conversion of the Series B non-voting convertible preferred stock (the "Series B Preferred Stock") into shares of Common Stock, each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.

F2 · shares: The shares of Series B Preferred Stock were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended.

F1 · derivative.exercise_date: Following stockholder approval of the conversion of the Series B non-voting convertible preferred stock (the "Series B Preferred Stock") into shares of Common Stock, each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.

F1 · derivative.expiration_date: Following stockholder approval of the conversion of the Series B non-voting convertible preferred stock (the "Series B Preferred Stock") into shares of Common Stock, each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.

F3 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000950170-23-066399 · ownership.xml · derivative · entry 4

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Fairmount Healthcare Co-Invest L.P. · CIK 0001982220 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Co-Invest L.P.

Disclosed balance after: 0

Underlying: Common Stock · 3,435,480 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations.

F1 · derivative.exercise_date: Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations.

F1 · derivative.expiration_date: Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund L.P., Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000950170-23-066399 · ownership.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Fairmount Healthcare Co-Invest L.P. · CIK 0001982220 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Co-Invest L.P.

Disclosed balance after: 3,435,480

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund L.P., Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-23-106378 · tm2327394-1_4seq1.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,928,503

F1 · shares: Consists of 24,670 shares of common stock purchased by Fairmount Healthcare Fund II LP ("Fund II").

F2 · price: This transaction was executed in multiple trades at prices ranging from $13.45 to $13.645. The price reported above reflects the weighted average purchase price. The Reporting Persons hereby undertake to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · ownership.nature: Consists of (i) 58,857 shares of common stock held of record by Fairmount Healthcare Fund LP ("Fund I"), (ii) 1,807,500 shares of common stock held of record by Fund II and (iii) 62,146 shares of common stock held of record by Fairmount SPV III, LLC. Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fund I and Fund II and is the Class A Member for Fairmount SPV III, LLC. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-23-104808 · tm2327182-1_4seq1.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,903,833

F1 · shares: Consists of 30,000 shares of common stock purchased by Fairmount Healthcare Fund II LP ("Fund II").

F2 · ownership.nature: Consists of (i) 58,857 shares of common stock held of record by Fairmount Healthcare Fund LP ("Fund I"), (ii) 1,782,830 shares of common stock held of record by Fund II and (iii) 62,146 shares of common stock held of record by Fairmount SPV III, LLC. Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fund I and Fund II and is the Class A Member for Fairmount SPV III, LLC. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000899243-23-019370 · doc4.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,873,833

F1 · shares: Consists of 30,000 shares of common stock purchased by Fairmount Healthcare Fund II LP ("Fund II").

F2 · ownership.nature: Consists of (i) 58,857 shares of common stock held of record by Fairmount Healthcare Fund LP ("Fund I"), (ii) 1,752,830 shares of common stock held of record by Fund II and (iii) 62,146 shares of common stock held of record by Fairmount SPV III, LLC. Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fund I and Fund II and is the Class A Member for Fairmount SPV III, LLC. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000950170-23-048022 · ownership.xml · nonDerivative · entry 2

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,843,833

F4 · shares: Consists of (i) 281 shares of common stock purchased by Fund I and (ii) 9,086 shares of common stock purchased by Fund II.

F5 · price: This transaction was executed in multiple trades at prices ranging from $10.90 to $12.50 The price reported above reflects the weighted average purchase price. The Reporting Persons hereby undertake to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

F6 · ownership.nature: Consists of (i) 58,857 shares of common stock held of record by Fund I, (ii) 1,722,830 shares of common stock held of record by Fund II and (iii) 62,146 shares of common stock held of record by Fairmount SPV III, LLC.

SEC source: 0000950170-23-048022 · ownership.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,834,466

F1 · shares: Consists of (i) 447 shares of common stock purchased by Fairmount Healthcare Fund LP ("Fund I") and (ii) 14,440 shares of common stock purchased by Fairmount Healthcare Fund II LP ("Fund II").

F2 · price: This transaction was executed in multiple trades at prices ranging from $10.415 to $11.00. The price reported above reflects the weighted average purchase price. The Reporting Persons hereby undertake to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · ownership.nature: Consists of (i) 58,576 shares of common stock held of record by Fund I, (ii) 1,713,744 shares of common stock held of record by Fund II and (iii) 62,146 shares of common stock held of record by Fairmount SPV III, LLC. Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fund I and Fund II and is the Class A Member for Fairmount SPV III, LLC. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000950170-23-048022 · ownership.xml · derivative · entry 3

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 6,500

Underlying: Common Stock · 6,500 shares

Expires 2033-09-10

F7 · derivative.exercise_date: This option represents a right to purchase a total of 6,500 shares of the Issuer's common stock, which will vest in full on the date that is the earlier of (i) the Issuer's 2024 Annual Meeting of Stockholders and (ii) September 11, 2024, subject to the Reporting Person's continued service to the Issuer.

F8 · ownership.nature: Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Kiselak holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock.